PanTheryx Presents Positive Results from Two New DiaResQ Studies at its 2019 International Scientific Symposium

New clinical data and case studies highlight the use of DiaResQ in a
range of real world settings, from hospitals to disaster relief, in its
first annual scientific meeting

BANGKOK–(BUSINESS WIRE)–PanTheryx, a biotechnology company committed to realizing the potential
of novel interventions to address a wide range of serious GI microbiome
related health conditions, announced today the results of two new
studies of its flagship
product DiaResQ^® at its first annual scientific symposium
for clinicians. The symposium titled “DiaResQ: A Scientific Update”
presented the findings along with case studies from around the globe.
The meeting was held at the Shangri La Hotel in Bangkok over two days,
March 1-2.

According to the World Health Organization, diarrhea is the second
leading cause of death for children under five, with an estimated 1.7
billion cases of childhood diarrhea occurring each year. More than 80%
of the cases occur in developing countries, including those in Africa
and South Asia. Standard of care is limited, and primarily focused on
symptom relief and preventing dehydration.

DiaResQ is a nutritional intervention that contains immune factors,
micronutrients, and macronutrients that work with the body to address
the underlying cause of diarrhea. In clinical trials, DiaResQ resolved a
majority of cases of pediatric diarrhea after one day of use. No serious
adverse events attributable to DiaResQ have been reported in its
clinical trials that have collectively enrolled over 1,000 children and
adults.

“We’re excited to bring together our international partners and key
opinion leaders to share the latest scientific substantiation of the
safety and efficacy of DiaResQ,” said Scott Hyman, senior vice president
at PanTheryx. “It’s vital that we continue to make progress in
addressing diarrhea, one of the leading causes of morbidity and
mortality worldwide. We are working closely with clinicians and our
partners to educate the medical community about the benefits of DiaResQ
and ensure it’s available
to everyone, especially children who are most at risk.”

About “DiaResQ: A Scientific Update” symposium

Attended by clinicians and KOLs from the international community, the
symposium was moderated by Dr. Alan Greene, MD. A renowned pediatrician,
author and international TEDx speaker, Dr. Greene is a leading authority
on child health and wellness and a leading voice in health innovation.

The latest clinical insights into DiaResQ were shared in the following
study presentations and case studies:

Clinical studies

“An Open Label Study to Evaluate the Efficacy and Acceptability of
DiaResQ in Children with Acute Childhood Diarrheal Disease” Presented
by Iqbal Memon, MD, Professor of Pediatrics and Department Head, Sir
Syed Hospital, Pakistan

• Study was a prospective, multicenter, randomized, open label study to
  assess the impact of DiaResQ on acute diarrhea in children age 6
  months to 4 years.
• 528 patients were enrolled, and randomized to receive standard of care
  or standard of care plus DiaResQ.
• Primary outcome measures included improvement in the frequency of
  diarrhea and vomiting, and improvement in stool consistency.
• Patients given the standard of care plus DiaResQ showed a
  statistically significant improvement in the stool frequency, stool
  consistency, and hydration status compared to standard of care alone.
  The product was well tolerated and no serious adverse events were
  reported.

“A Comparative Study on the Efficacy of Colostrum and Whole Egg Blend
Dietary Supplementation with Standard Therapy versus Standard Therapy
Alone In the Management of Acute Watery Non-bloody Diarrhea In Children
Aged 1 to 5 Years Old” Presented by Jennie Ang Wong, MD, Fe del
Mundo Medical Center Philippines, Pamantasan ng Lungsod ng
Maynila-Ospital ng Maynila Medical Center Philippines

• Study was a prospective, randomized, open label study to evaluate the
  efficacy of DiaResQ with standard therapy vs standard therapy alone in
  the management of acute watery non-bloody diarrhea.
• 128 patients age 1-5 were enrolled, and half (n=64) were
  systematically assigned to the control group and the other half to
  receive standard of care plus DiaResQ.
• Primary outcomes measures included stool frequency, stool consistency,
  duration of illness, and doctor reported improved well-being.
• Patients given the standard of care plus DiaResQ showed a significant
  improvement in the frequency of diarrhea, improvement in stool
  consistency, shortened duration of illness, and improved doctor
  reported well-being. No serious adverse events were reported.

Case studies

Case studies were presented by:

• John Oliveros, MD, Assistant Professor, Pediatrics
  Department, Jose P. Rizal College of Medicine, Xavier University,
  Cagayan de Oro City, Philippines. This case study shared Dr.
  Oliveros’s experience using DiaResQ in a clinical setting.
• Dr. Ameleen Bangayan, MD, Pediatric Gastroenterologist, Davao
  Doctors Hospital and Davao Medical Center. Dr. Bangayan shared her
  experience using DiaResQ at her medical center in the Philippines.
• Dr. Rifa Atuzzaqiyah, Pediatrician, RSUD Dr. Soedjono, Selong,
  Lombok Timur, NTB, Indonesia. This case study explored the use of
  DiaResQ to support disaster relief efforts in Indonesia after the 2018
  Lombok earthquake.

To learn more about these clinical trials and case studies or request
more information, contact info@pantheryx.com.

About DiaResQ

DiaResQ® is a nutritional intervention that contains immune factors,
micronutrients, and macronutrients that work with the body to address
the underlying cause of diarrhea — not just the symptoms. In clinical
trials, DiaResQ resolved a majority of cases of pediatric diarrhea after
one day of use. No serious adverse events attributable to DiaResQ have
been reported in its clinical trials that have collectively enrolled
over 1,000 children and adults.

DiaResQ was recognized as one of thirty
leading healthcare innovations with great promise to transform
global health by 2030 and to help accelerate progress toward the United
Nations Sustainable Development Goals health targets.

About PanTheryx

PanTheryx is a biotechnology company committed to realizing the
potential of novel interventions to address a wide range of serious GI
microbiome related health conditions. The company is also the premier
supplier of bovine colostrum, and leverages its vertical integration to
develop and commercialize first-in-class therapeutics, with products
developed from its patented technology platform spanning the range of
nutritional interventions to biologics. Founded in 2007, PanTheryx is
headquartered in Boulder, Colorado, and has production facilities in
Phoenix, AZ, and Ripon, CA.

For more information, please visit PanTheryx.com.

Contacts

Media:
Jess Teilborg – Vice President, Marketing
(720)
417-7325
Jessica.Teilborg@pantheryx.com